Christine A. Iacobuzio-Donahue, M.D., Ph.D.

2012 Keynote speaker for our event “A Night At the Kentucky Derby”


Experience is Important

Surgeons at Johns Hopkins performed more pancreatic cancer resections than any other institution in the world.

Biographical information

 

Christine A. Iacobuzio-Donahue, M.D., Ph.D. is a Professor in the Departments of Pathology and Oncology at Johns Hopkins University School of Medicine in Baltimore, Maryland.  She received her bachelor?s degree in biology from Adelphi University in New York, and her medical degree and doctoral degree in pathology from Boston University.  Dr. Iacobuzio-Donahue came to Johns Hopkins in 1998, first for her residency in academic pathology than a fellowship in gastrointestinal/liver pathology.  She joined the Department of Pathology faculty in 2003.  Dr. Iacobuzio-Donahue is a board certified anatomic pathologist with specialty training in gastrointestinal pathology and molecular genetics of gastrointestinal neoplasia.  She runs an R01 funded laboratory focused on the mechanisms of pancreatic cancer metastasis at Johns Hopkins Medicine.  Dr. Iacobuzio-Donahue has published more than 130 peer-reviewed manuscripts, most of which are related to the molecular biology and genetics of pancreatic carcinogenesis and most recently the clonal evolution of pancreatic cancer from its inception through metastasis to distant sites.


In 2003, Dr. Iacobuzio-Donahue founded and directs the Gastrointestinal Cancer Rapid Medical Donation Program that serves as a basis for collecting primary and metastatic tissues from patients with end stage gastrointestinal cancer, predominantly pancreatic cancer. 

This unique program allows patients with terminal, metastatic cancer to agree to undergo a rapid autopsy for research purposes.  These tissues are then analyzed by her laboratory using a variety of high-throughput methods including whole genome high-density SNP arrays, gene sequencing and oligonucleotide microarrays in an effort to identify novel areas of homozygous deletion and/or genetic alteration specifically associated with cancer metastasis.  Candidate genes identified are further evaluated using a variety of in vivo mouse models to explore their functional relationship to tumor progression, invasion and metastasis.